Department of Pharmaceutical Chemistry, King Abdulaziz University, Jeddah, Saudi Arabia.
Arch Pharm (Weinheim). 2010 Feb;343(2):73-80. doi: 10.1002/ardp.200900219.
LE 300 represents a structurally novel type of antagonists acting preferentially at the dopamine D(1)/D(5 )receptors and the serotonin 5-HT(2A )receptor. This compound consists of a ten-membered central azecine ring fused to an indole ring on one side and a benzene moiety on the other side. To estimate the importance of the indole and / or phenyl moieties in this highly active benz-indolo-azecine, both rings were removed and replaced with a 1H-pyrrole counterpart. Accordingly, some new analogs of LE 300 namely, pyrrolo[2,3-g]indolizine, pyrrolo[3,2-a]quinolizine rings and their corresponding dimethylpyrrolo[2,3-d]azonine, and dimethylpyrrolo[2,3-d]azecine were synthesized to be evaluated for their activity at the 5-HT(2A) and dopamine D(1), D(2L), D(4), D(5) receptors in relation to LE 300. In addition, their activity at the H(1)-histamine receptors was also determined. The results suggested that the rigid pyrrolo[2,3-g]indolizine 7 and pyrrolo[3,2-a]quinolizine 8 analogs lacked biological activity in the adopted three bioassays. However, their corresponding flexible pyrrolo[2,3-d]azonine 11 and pyrrolo[2,3-d]azecine 12 derivatives revealed weak partial agonistic activity and weak antagonistic potency at the serotonin 5-HT(2A )and histamine H(1 )receptors, respectively. Meanwhile, they showed no affinity to any of the four utilized dopamine receptors. Variation in ring size did not contribute to a significant influence on the three tested bioactivities. Removal of the hydrophobic moiety (phenyl ring) and replacement of the indole moiety with a 1H-pyrrole counterpart led to a dramatic alteration in the profile of activity of such azecine-type compounds.
LE 300 代表了一种结构新颖的拮抗剂,优先作用于多巴胺 D(1)/D(5)受体和 5-羟色胺 5-HT(2A)受体。该化合物由一个十元中环氮杂环庚烷与一侧的吲哚环和另一侧的苯部分融合而成。为了评估该高度活性的苯并吲哚氮杂环庚烷中吲哚和/或苯基部分的重要性,去除了这两个环并用 1H-吡咯取代。因此,一些 LE 300 的新类似物,即吡咯并[2,3-g]吲哚嗪、吡咯并[3,2-a]喹啉嗪环及其相应的二甲基吡咯并[2,3-d]氮杂环庚烷和二甲基吡咯并[2,3-d]氮杂环庚烷被合成并评估了它们在 5-HT(2A)和多巴胺 D(1)、D(2L)、D(4)、D(5)受体中的活性与 LE 300 相比。此外,还测定了它们在 H(1)-组胺受体上的活性。结果表明,刚性吡咯并[2,3-g]吲哚嗪 7 和吡咯并[3,2-a]喹啉嗪 8 类似物在采用的三种生物测定中缺乏生物活性。然而,它们相应的柔性吡咯并[2,3-d]氮杂环庚烷 11 和吡咯并[2,3-d]氮杂环庚烷 12 衍生物在 5-HT(2A)和组胺 H(1)受体上分别显示出弱部分激动活性和弱拮抗作用。同时,它们对四种所测多巴胺受体均无亲和力。环大小的变化对三种测试的生物活性没有显著影响。去除疏水性部分(苯环)并用 1H-吡咯取代吲哚部分导致这种氮杂环庚烷类化合物的活性谱发生显著改变。